Cargando…
P639: ZANUBRUTINIB (ZANU) VS BENDAMUSTINE + RITUXIMAB (BR) IN PATIENTS (PTS) WITH TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): EXTENDED FOLLOW-UP OF THE SEQUOIA STUDY
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429085/ http://dx.doi.org/10.1097/01.HS9.0000969460.15364.af |
| _version_ | 1785090626220457984 |
|---|---|
| author | Munir, Talha Shadman, Mazyar Robak, Tadeusz R. Brown, Jennifer Kahl, Brad Ghia, Paolo Giannopoulos, Krzysztof Simkovic, Martin Österberg, Anders Laurenti, Luca Walker, Patricia Opat, Stephen Ciepluch, Hanna Greil, Richard Hanna, Merit Tani, Monica Trneny, Marek M. Brander, Danielle W. Flinn, Ian Grosicki, Sebastian Verner, Emma Tedeschi, Alessandra De Guibert, Sophie Tumyan, Gayane Laribi, Kamel Antonio Garcia Marco, Jose LI, Jianyong Tian, Tian Ramakrishnan, Vanitha Liu, Yu Szeto, Andy Paik, Jason Cohen, Aileen Tam, Constantine Jurczak, Wojciech |
| author_facet | Munir, Talha Shadman, Mazyar Robak, Tadeusz R. Brown, Jennifer Kahl, Brad Ghia, Paolo Giannopoulos, Krzysztof Simkovic, Martin Österberg, Anders Laurenti, Luca Walker, Patricia Opat, Stephen Ciepluch, Hanna Greil, Richard Hanna, Merit Tani, Monica Trneny, Marek M. Brander, Danielle W. Flinn, Ian Grosicki, Sebastian Verner, Emma Tedeschi, Alessandra De Guibert, Sophie Tumyan, Gayane Laribi, Kamel Antonio Garcia Marco, Jose LI, Jianyong Tian, Tian Ramakrishnan, Vanitha Liu, Yu Szeto, Andy Paik, Jason Cohen, Aileen Tam, Constantine Jurczak, Wojciech |
| author_sort | Munir, Talha |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10429085 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104290852023-08-17 P639: ZANUBRUTINIB (ZANU) VS BENDAMUSTINE + RITUXIMAB (BR) IN PATIENTS (PTS) WITH TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): EXTENDED FOLLOW-UP OF THE SEQUOIA STUDY Munir, Talha Shadman, Mazyar Robak, Tadeusz R. Brown, Jennifer Kahl, Brad Ghia, Paolo Giannopoulos, Krzysztof Simkovic, Martin Österberg, Anders Laurenti, Luca Walker, Patricia Opat, Stephen Ciepluch, Hanna Greil, Richard Hanna, Merit Tani, Monica Trneny, Marek M. Brander, Danielle W. Flinn, Ian Grosicki, Sebastian Verner, Emma Tedeschi, Alessandra De Guibert, Sophie Tumyan, Gayane Laribi, Kamel Antonio Garcia Marco, Jose LI, Jianyong Tian, Tian Ramakrishnan, Vanitha Liu, Yu Szeto, Andy Paik, Jason Cohen, Aileen Tam, Constantine Jurczak, Wojciech Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10429085/ http://dx.doi.org/10.1097/01.HS9.0000969460.15364.af Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Munir, Talha Shadman, Mazyar Robak, Tadeusz R. Brown, Jennifer Kahl, Brad Ghia, Paolo Giannopoulos, Krzysztof Simkovic, Martin Österberg, Anders Laurenti, Luca Walker, Patricia Opat, Stephen Ciepluch, Hanna Greil, Richard Hanna, Merit Tani, Monica Trneny, Marek M. Brander, Danielle W. Flinn, Ian Grosicki, Sebastian Verner, Emma Tedeschi, Alessandra De Guibert, Sophie Tumyan, Gayane Laribi, Kamel Antonio Garcia Marco, Jose LI, Jianyong Tian, Tian Ramakrishnan, Vanitha Liu, Yu Szeto, Andy Paik, Jason Cohen, Aileen Tam, Constantine Jurczak, Wojciech P639: ZANUBRUTINIB (ZANU) VS BENDAMUSTINE + RITUXIMAB (BR) IN PATIENTS (PTS) WITH TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): EXTENDED FOLLOW-UP OF THE SEQUOIA STUDY |
| title | P639: ZANUBRUTINIB (ZANU) VS BENDAMUSTINE + RITUXIMAB (BR) IN PATIENTS (PTS) WITH TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): EXTENDED FOLLOW-UP OF THE SEQUOIA STUDY |
| title_full | P639: ZANUBRUTINIB (ZANU) VS BENDAMUSTINE + RITUXIMAB (BR) IN PATIENTS (PTS) WITH TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): EXTENDED FOLLOW-UP OF THE SEQUOIA STUDY |
| title_fullStr | P639: ZANUBRUTINIB (ZANU) VS BENDAMUSTINE + RITUXIMAB (BR) IN PATIENTS (PTS) WITH TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): EXTENDED FOLLOW-UP OF THE SEQUOIA STUDY |
| title_full_unstemmed | P639: ZANUBRUTINIB (ZANU) VS BENDAMUSTINE + RITUXIMAB (BR) IN PATIENTS (PTS) WITH TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): EXTENDED FOLLOW-UP OF THE SEQUOIA STUDY |
| title_short | P639: ZANUBRUTINIB (ZANU) VS BENDAMUSTINE + RITUXIMAB (BR) IN PATIENTS (PTS) WITH TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): EXTENDED FOLLOW-UP OF THE SEQUOIA STUDY |
| title_sort | p639: zanubrutinib (zanu) vs bendamustine + rituximab (br) in patients (pts) with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (cll/sll): extended follow-up of the sequoia study |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429085/ http://dx.doi.org/10.1097/01.HS9.0000969460.15364.af |
| work_keys_str_mv | AT munirtalha p639zanubrutinibzanuvsbendamustinerituximabbrinpatientsptswithtreatmentnaivechroniclymphocyticleukemiasmalllymphocyticlymphomacllsllextendedfollowupofthesequoiastudy AT shadmanmazyar p639zanubrutinibzanuvsbendamustinerituximabbrinpatientsptswithtreatmentnaivechroniclymphocyticleukemiasmalllymphocyticlymphomacllsllextendedfollowupofthesequoiastudy AT robaktadeusz p639zanubrutinibzanuvsbendamustinerituximabbrinpatientsptswithtreatmentnaivechroniclymphocyticleukemiasmalllymphocyticlymphomacllsllextendedfollowupofthesequoiastudy AT rbrownjennifer p639zanubrutinibzanuvsbendamustinerituximabbrinpatientsptswithtreatmentnaivechroniclymphocyticleukemiasmalllymphocyticlymphomacllsllextendedfollowupofthesequoiastudy AT kahlbrad p639zanubrutinibzanuvsbendamustinerituximabbrinpatientsptswithtreatmentnaivechroniclymphocyticleukemiasmalllymphocyticlymphomacllsllextendedfollowupofthesequoiastudy AT ghiapaolo p639zanubrutinibzanuvsbendamustinerituximabbrinpatientsptswithtreatmentnaivechroniclymphocyticleukemiasmalllymphocyticlymphomacllsllextendedfollowupofthesequoiastudy AT giannopouloskrzysztof p639zanubrutinibzanuvsbendamustinerituximabbrinpatientsptswithtreatmentnaivechroniclymphocyticleukemiasmalllymphocyticlymphomacllsllextendedfollowupofthesequoiastudy AT simkovicmartin p639zanubrutinibzanuvsbendamustinerituximabbrinpatientsptswithtreatmentnaivechroniclymphocyticleukemiasmalllymphocyticlymphomacllsllextendedfollowupofthesequoiastudy AT osterberganders p639zanubrutinibzanuvsbendamustinerituximabbrinpatientsptswithtreatmentnaivechroniclymphocyticleukemiasmalllymphocyticlymphomacllsllextendedfollowupofthesequoiastudy AT laurentiluca p639zanubrutinibzanuvsbendamustinerituximabbrinpatientsptswithtreatmentnaivechroniclymphocyticleukemiasmalllymphocyticlymphomacllsllextendedfollowupofthesequoiastudy AT walkerpatricia p639zanubrutinibzanuvsbendamustinerituximabbrinpatientsptswithtreatmentnaivechroniclymphocyticleukemiasmalllymphocyticlymphomacllsllextendedfollowupofthesequoiastudy AT opatstephen p639zanubrutinibzanuvsbendamustinerituximabbrinpatientsptswithtreatmentnaivechroniclymphocyticleukemiasmalllymphocyticlymphomacllsllextendedfollowupofthesequoiastudy AT ciepluchhanna p639zanubrutinibzanuvsbendamustinerituximabbrinpatientsptswithtreatmentnaivechroniclymphocyticleukemiasmalllymphocyticlymphomacllsllextendedfollowupofthesequoiastudy AT greilrichard p639zanubrutinibzanuvsbendamustinerituximabbrinpatientsptswithtreatmentnaivechroniclymphocyticleukemiasmalllymphocyticlymphomacllsllextendedfollowupofthesequoiastudy AT hannamerit p639zanubrutinibzanuvsbendamustinerituximabbrinpatientsptswithtreatmentnaivechroniclymphocyticleukemiasmalllymphocyticlymphomacllsllextendedfollowupofthesequoiastudy AT tanimonica p639zanubrutinibzanuvsbendamustinerituximabbrinpatientsptswithtreatmentnaivechroniclymphocyticleukemiasmalllymphocyticlymphomacllsllextendedfollowupofthesequoiastudy AT trnenymarek p639zanubrutinibzanuvsbendamustinerituximabbrinpatientsptswithtreatmentnaivechroniclymphocyticleukemiasmalllymphocyticlymphomacllsllextendedfollowupofthesequoiastudy AT mbranderdanielle p639zanubrutinibzanuvsbendamustinerituximabbrinpatientsptswithtreatmentnaivechroniclymphocyticleukemiasmalllymphocyticlymphomacllsllextendedfollowupofthesequoiastudy AT wflinnian p639zanubrutinibzanuvsbendamustinerituximabbrinpatientsptswithtreatmentnaivechroniclymphocyticleukemiasmalllymphocyticlymphomacllsllextendedfollowupofthesequoiastudy AT grosickisebastian p639zanubrutinibzanuvsbendamustinerituximabbrinpatientsptswithtreatmentnaivechroniclymphocyticleukemiasmalllymphocyticlymphomacllsllextendedfollowupofthesequoiastudy AT verneremma p639zanubrutinibzanuvsbendamustinerituximabbrinpatientsptswithtreatmentnaivechroniclymphocyticleukemiasmalllymphocyticlymphomacllsllextendedfollowupofthesequoiastudy AT tedeschialessandra p639zanubrutinibzanuvsbendamustinerituximabbrinpatientsptswithtreatmentnaivechroniclymphocyticleukemiasmalllymphocyticlymphomacllsllextendedfollowupofthesequoiastudy AT deguibertsophie p639zanubrutinibzanuvsbendamustinerituximabbrinpatientsptswithtreatmentnaivechroniclymphocyticleukemiasmalllymphocyticlymphomacllsllextendedfollowupofthesequoiastudy AT tumyangayane p639zanubrutinibzanuvsbendamustinerituximabbrinpatientsptswithtreatmentnaivechroniclymphocyticleukemiasmalllymphocyticlymphomacllsllextendedfollowupofthesequoiastudy AT laribikamel p639zanubrutinibzanuvsbendamustinerituximabbrinpatientsptswithtreatmentnaivechroniclymphocyticleukemiasmalllymphocyticlymphomacllsllextendedfollowupofthesequoiastudy AT antoniogarciamarcojose p639zanubrutinibzanuvsbendamustinerituximabbrinpatientsptswithtreatmentnaivechroniclymphocyticleukemiasmalllymphocyticlymphomacllsllextendedfollowupofthesequoiastudy AT lijianyong p639zanubrutinibzanuvsbendamustinerituximabbrinpatientsptswithtreatmentnaivechroniclymphocyticleukemiasmalllymphocyticlymphomacllsllextendedfollowupofthesequoiastudy AT tiantian p639zanubrutinibzanuvsbendamustinerituximabbrinpatientsptswithtreatmentnaivechroniclymphocyticleukemiasmalllymphocyticlymphomacllsllextendedfollowupofthesequoiastudy AT ramakrishnanvanitha p639zanubrutinibzanuvsbendamustinerituximabbrinpatientsptswithtreatmentnaivechroniclymphocyticleukemiasmalllymphocyticlymphomacllsllextendedfollowupofthesequoiastudy AT liuyu p639zanubrutinibzanuvsbendamustinerituximabbrinpatientsptswithtreatmentnaivechroniclymphocyticleukemiasmalllymphocyticlymphomacllsllextendedfollowupofthesequoiastudy AT szetoandy p639zanubrutinibzanuvsbendamustinerituximabbrinpatientsptswithtreatmentnaivechroniclymphocyticleukemiasmalllymphocyticlymphomacllsllextendedfollowupofthesequoiastudy AT paikjason p639zanubrutinibzanuvsbendamustinerituximabbrinpatientsptswithtreatmentnaivechroniclymphocyticleukemiasmalllymphocyticlymphomacllsllextendedfollowupofthesequoiastudy AT cohenaileen p639zanubrutinibzanuvsbendamustinerituximabbrinpatientsptswithtreatmentnaivechroniclymphocyticleukemiasmalllymphocyticlymphomacllsllextendedfollowupofthesequoiastudy AT tamconstantine p639zanubrutinibzanuvsbendamustinerituximabbrinpatientsptswithtreatmentnaivechroniclymphocyticleukemiasmalllymphocyticlymphomacllsllextendedfollowupofthesequoiastudy AT jurczakwojciech p639zanubrutinibzanuvsbendamustinerituximabbrinpatientsptswithtreatmentnaivechroniclymphocyticleukemiasmalllymphocyticlymphomacllsllextendedfollowupofthesequoiastudy |